Ceritinib

Overview

An anaplastic lymphoma kinase (ALK)-positive inhibitor used for the treatment of non-small cell lung cancer (NSCLC). It less potently inhibits IGF-1R, InsR, and STK22D and IC50 value is 8, 7, and 23 nM. LDK378 is also minimally effective against a panel of other kinases. In Sep 2016, Interim adverse events and efficacy data from phase III ASCEND-4 trial in non small cell lung cancer released by Novartis. In Oct 2016, efficacy data from the phase III ASCEND-3 and ASCEND-5 trial in non small cell lung cancer was presented.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | ALK

Product Information

• Catalog No.: B0084-462148
• CAS No.: 1032900-25-6
• Molecular Formula: C28H36ClN5O3S
• Molecular Weight: 558.14
• Purity: ≥98%
• Storage: Store at -20°C
• Solubility: Soluble in DMSO.

Source

Original product source